Health ❯ Healthcare ❯ Drug Development

Clinical Trials

FDA Approval Real-World Evidence Eli Lilly Regulatory Approval Side Effects Biosimilar Approval Process Leqembi Innovative Therapies GBT-601 Pharmaceutical Innovations Alzheimer's Disease Neuropharmacology Neurodegenerative Diseases Randomized Controlled Trials Market Dynamics AI in Medicine CAPLYTA Late-Stage Studies Weight-loss Medications Repurposed Medications Gene Therapy Innovations Antibiotic Resistance CNS Disorders Combination Therapies mRNA Vaccines Alzheimer's Treatments Oncology Camizestrant Immunology Treatments NHS Innovations Preclinical Research Market Trends Neuropsychiatric Drugs Bronchodilators Chronic Lung Conditions Wegovy Monoclonal Antibodies Safety Monitoring Pain Relief Medications Cancer Pain Relief Orforglipron Efficacy Studies Gilead Sciences Phase III Studies Amyloid Immunotherapy Phase 3 Clinical Studies Lecanemab Phase 1 Trials Targeted Therapy Future Research Directions Metabolic Disease Therapies Phase 2 Trials Epinephrine Alternatives Tumor-Infiltrating Lymphocytes Alzheimer's Disease Treatments Regulatory Exclusivity

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

The offer targets Ixo-vec, a one-time treatment for wet age-related macular degeneration now in a late-stage trial.

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use